Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
January 28, 2021
Nanologica

Nanologica signs collaboration agreement with Zentiva for the use of NLAB drug delivery platforms

Nanologica signs collaboration agreement with Zentiva for the use of NLAB drug delivery platforms

-
Nanologica
-
January 28, 2021

A collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements.  

The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement.

We first met Zentiva during BIO-Europe in 2019. Since then, we have had a continuous dialogue as they see substantial potential in our drug delivery platforms for several of their development projects. With this agreement in place, we now look forward to future collaborations”, says Andreas Bhagwani, CEO of Nanologica.

Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.

For further information, please contact:

Johanna Johansson, IR Nanologica

Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com

Last updated:
January 28, 2021

Nanologica

Nanologica combines unique know-how in the field of materials technology with a genuine interest in solving real problems in life science.

Click here to read more about us!
Get in touch with us!
Visit us

Forskargatan 20G
SE-151 36 Södertälje, Sweden

Send us mail

A collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements.  

The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement.

We first met Zentiva during BIO-Europe in 2019. Since then, we have had a continuous dialogue as they see substantial potential in our drug delivery platforms for several of their development projects. With this agreement in place, we now look forward to future collaborations”, says Andreas Bhagwani, CEO of Nanologica.

Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.

For further information, please contact:

Johanna Johansson, IR Nanologica

Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com

Last updated:
January 28, 2021

Nanologica

Nanologica combines unique know-how in the field of materials technology with a genuine interest in solving real problems in life science.

Click here to read more about us!
Get in touch with us!
Visit us

Forskargatan 20G
SE-151 36 Södertälje, Sweden

Send us mail